InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,393.61
(
0.59%
)
Post# of 252189
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119839
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 224495

Saturday, 04/06/2019 3:14:49 PM

Saturday, April 06, 2019 3:14:49 PM

Post# of 252189
ENTA was founded in 1995; its mission from the start has been to discover small-molecule drugs for infectious diseases. Hiring the best available scientists was (and is) an integral part of the business plan.

By 2006, ENTA had sufficient expertise in HCV to trigger a fairly lucrative pre-clinical-stage deal with Abbott (#msg-15492225).

ENTA’s track record is not blemish free, however. Its antibacterial program failed. Even with great scientists, you need some luck to be successful in the drug business.

p.s. ENTA’s NASH program is the company’s first foray outside of infectious diseases.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up